Conference Coverage

Study: Stick with TMP-SMX for posttransplant PJP prophylaxis


 

REPORTING FROM ALF 2018


Nocardiosis occurred mainly in patients on high doses of corticosteroids for graft-versus-host disease, and 8 of the 10 affected patients were not receiving TMP-SMX for PJP prophylaxis; 7 were on atovaquone, and 1 was on intravenous pentamidine, Mr. Molina said.

The findings suggest that TMP-SMX should remain the agent of choice for PJP prophylaxis in HSCT recipients and have prompted a return to the older protocol of high-dose TMP-SMX for this purpose at UCLA, he said.

“Unless a patient is totally intolerant of TMP-SMX, prophylaxis with atovaquone or pentamidine should be avoided,” he concluded.

Mr. Molina reported having no financial disclosures. The Acute Leukemia Forum is held by Hemedicus, which is owned by the same company as this news organization.

SOURCE: Molina A et al., ALF 2018, Poster Session.

Pages

Recommended Reading

Cancer groups offer guidance on immune-related adverse events
MDedge Hematology and Oncology
Outpatient CAR T infusions feasible using liso-cel
MDedge Hematology and Oncology
Nonmyeloablative conditioning gets a radiation boost for severe hemoglobinopathies
MDedge Hematology and Oncology
KD025 shows promise for steroid-dependent cGVHD
MDedge Hematology and Oncology
CAR T before transplant yields durable remission in B-cell malignancies
MDedge Hematology and Oncology
Xenon imaging could detect lung involvement after HSCT
MDedge Hematology and Oncology
Low microbiota diversity linked to poor survival after transplant
MDedge Hematology and Oncology
Ibrutinib preserves immune memory while fighting cGVHD
MDedge Hematology and Oncology
Posttransplant cyclophosphamide helped reduce GVHD rates
MDedge Hematology and Oncology
High engraftment with new umbilical transplant technique
MDedge Hematology and Oncology